Alternative Name
BTK, Bruton tyrosine kinase
Methodology
Molecular
Test Description

Bi-directional sequencing to detect the C481S mutation in exon 15 and other potential mutations within the amino acid range C464 to M509. Testing is available separately or in combination with PLC-gamma-2 in the BTK Inhibitor Acquired Resistance Panel. NeoGenomics recommends ordering the combination Panel.

Clinical Significance

Bruton's tyrosine kinase (BTK) is involved in multiple signaling pathways regulating proliferation, differentiation, and survival of B-lineage lymphoid cells. Multiple BTK inhibitors are in use (such as ibrutinib and dasatanib) and in clinical trials. Mutations are associated with acquired or secondary resistance to ibrutinib arising after initial response in B-cell disorders including CLL and mantle cell lymphoma.

Specimen Requirements
  • Peripheral blood: 5 mL in EDTA tube.
  • Bone marrow: 2 mL in EDTA tube.
  • FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
81233
Turnaround Time

10 days

Level of Service
Global

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.